Source: International Congress 2016 – Asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Caroline Gouder (Kappara, Malta), Caroline Gouder, Rachelle Asciak, Stephen Montefort. The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta. Eur Respir J 2016; 48: Suppl. 60, 4115

Member's Comments

No comment yet.

Related content which might interest you: APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Long-term using of omalizumab in children with atopic severe persistent non-controlled asthma Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013 Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Treatment of uncontrolled, severe persistent allergic (IgE-mediated) asthma with omalizumab in a real-life setting in Germany Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 One year following a real life experience of omalizumab for moderate to severe persistent allergic asthma in Malta Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Patients with allergic and eosinophilic asthma in the German severe asthma registry Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 First clinical trial of a new IgE-adsorber in allergic asthma Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma Year: 2015 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma whether due to seasonal allergens or to perennial allergens Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Predictors of severe asthma exacerbations, poor asthma control and beta-agonist overuse in adult asthma Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Determinants of non-adherence to pharmacologic allergic rhinitis treatment Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013